The U.S. prostate cancer testing market is anticipated to reach $1,901.6 million in 2030 from $544.1 million in 2021, with a CAGR of 14.7%, during the forecast period 2022-2030. The growth in the U.S. prostate cancer testing market is expected to be driven by high investments in the field of cancer research and the rising prevalence of prostate cancer in U.S. In addition, the focus of business leaders is establishing a deep understanding to address the unmet needs in clinical research to understand the prostate cancer market.

Market Lifecycle Stage

The U.S. prostate cancer testing market is in progressing phase. PSA screening or testing in a general population has increased the incidence of prostate cancer in recent decades. In addition, prostate cancer testing is essential in precision medicine because it assures the safe and successful use of tailored therapies. The majority of the companies in the U.S. prostate cancer testing market provide biomarker tests that are urine, blood, and tissue-based, as well as testing services. Furthermore, applications of prostate cancer testing are primarily clinical and research.

Impact

One of the main reasons for the expansion of the prostate cancer testing market in the upcoming years is the rise in prostate cancer cases. Prostate cancer is the second most frequent disease diagnosed in men, and its frequency is rising across the globe. Prostate cancer is thought to be diagnosed in one million additional cases worldwide each year. Due to an aging population, growing urbanization, and accompanying lifestyle changes, the overall incidence of prostate cancer has increased over the past few decades.

Impact of COVID-19

During the coronavirus disease 2019 (COVID-19) pandemic, a number of disease models issued warnings about an excess of cancer fatalities brought on by missed cancer screenings as a result of the general population’s quarantine and a lack of healthcare resources. The COVID-19 pandemic has had a negative impact on early diagnosis in the specific case of prostate cancer, the second most common cancer in men, by reducing participation in screening programs and on time from diagnostic testing to surgery/radiotherapy, which may translate into a worse prostate-cancer-specific death rate in the coming years. Additionally, in other areas, including Florida, state governments disallowed non-essential healthcare services.

Significant reductions in cancer screenings were seen in the early stages of the COVID-19 pandemic. According to a research paper published in January 2022 by the University of Florida, screenings for prostate cancer were reduced by 74%. Due to these screening figures, there may have been thousands more cancer deaths in the U.S. than were registered.

For instance, prostate-specific antigen (PSA) testing rates and the identification of several urological malignancies, including prostate cancer, have been found to be declining in significantly afflicted populations. Several Australian urologists worry that men with possibly curable prostate cancer may have missed their chance for a cure due to low screening test uptake during the lockdowns of 2020. According to a research paper published by BMC Urology in June 2022, a total of 4,048,099 PSA tests and 118,328 prostate biopsies were performed in Australia over the six years of data analysis. In the years 2019 and 2020, 68,429 prostate magnetic resonance imaging (MRI) were performed. Between 2015 and 2019, there were, on average, 19,573 prostate biopsies and 678,082 PSA testing performed per year.

Market Segmentation:

Segmentation 1: by Biomarker Type

• Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA)
• Pre-Biopsy/Post-Negative Biopsy Testing
• Post-Biopsy Tissue Testing

Based on biomarker type, the pre-biopsy test in the U.S. prostate cancer testing market is expected to be dominated by the biomarker type segment. This is due to the increasing popularity of prostate cancer testing and rising awareness related to prostate cancer testing.

Segmentation 2: by Application

• Diagnostics Biomarkers
• Prognostics Biomarkers

Based on application, the U.S. prostate cancer testing market is dominated by the diagnostics biomarkers segment owing to the rising R&D activity focused on the development of prostate cancer testing. The diagnosis of prostate cancer has developed a new molecular-based diagnostics technology. To detect clinically relevant cancer upon diagnosis, several tools or therapeutic options are required to improve the patient’s quality of life.

Segmentation 3: by End User

• Cancer Research Institutes
• Diagnostic Laboratories
• Hospitals and Clinics
• Ambulatory Surgical Center (ASCs)
• Others

As of 2021, the U.S. prostate cancer testing market (by end user) was dominated by ambulatory surgical centers (ASCs), holding a 28.55% market share with a market value of $155.3 million.

Segmentation 4: by Region

• Northeast U.S.
• Midwest U.S
• South U.S.
• West U.S.

The TAM of the pre-biopsy/post-negative biopsy testing segment is expected to grow at a CAGR of 4.5% during the forecast period 2022-2030 in the South U.S. prostate cancer testing market. Several established diagnostics manufacturers in this region who are focusing on expanding their portfolios in prostate cancer testing and are collaborating with service providers and pharmaceutical giants to co-market prostate cancer testing solutions with its complementary precision medicine solutions. Moreover, the U.S. government is currently undertaking several initiatives to develop tests for cancer and provide funds to new start-ups in the cancer diagnostics field.

Recent Developments in the U.S. Prostate Cancer Testing Market

• In September 2022, Veracyte, Inc. announced the publishing of data in the Journal of the National Cancer Institute to demonstrate the company’s decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.
• In August 2019, BioReference Laboratories, Inc. announced the selection by The IPA Association of America (TIPAAA) as its provider of laboratory services and to assist with data analytics for its members’ patients. The agreement is designed to enhance patient care and offers collaborative health management tools to TIPAAA members, which includes more than 667 medical organizations in 39 states. The members can have convenient access to BioReference’s comprehensive laboratory testing menu, including routine and specialty tests, as well as the 4Kscore for detecting aggressive prostate cancer.
• In June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. The grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients.

Demand – Drivers and Limitations

The following are the demand drivers for the U.S. prostate cancer testing market:

• Rising Prevalence of Prostate Cancer in the U.S.
• Increasing Number of Prostate Cancer Screening and Testing
• Government Initiatives Related to Prostate Cancer

The market is expected to face some limitations due to the following challenges:

• High Probability of False Positives during Prostate Cancer Testing
• Clinical Gaps Related to Prostate Cancer Testing

How can this report add value to an organization?

Workflow/Innovation Strategy: The workflow segment helps the reader understand the two prostate cancer testing, i.e., initial evaluation: prostate-specific antigen (total PSA, free PSA), pre-biopsy/post-negative biopsy testing, post-biopsy tissue testing, which further aid in diagnosis. Moreover, the study provides the reader with a detailed understanding of the different applications of prostate cancer testing in clinical and research applications.

Growth/Marketing Strategy: Prostate cancer testing is being used for both research and clinical application. Various companies are providing urine and blood, and tissue-based biomarkers that aid in the diagnosis, which is also the key strategy for market players to excel in the current prostate cancer testing market.

Competitive Strategy: Key players in the U.S. prostate cancer testing market are analyzed and profiled in the study, including manufacturers who are involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the U.S. prostate cancer testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled:

• Abbott.
• Abcam plc.
• Agilent Technologies, Inc.
• Bio-Techne. (ExoDx)
• Cleveland Diagnostics, Inc.
• Danaher. (Beckman Coulter, Inc.)
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.)
• H.U. Group Holdings, Inc. (Fujeribio)
• mdxhealth.
• Siemens Healthcare GmbH
• Myriad Genetics, Inc.
• NeoGenomics Laboratories.
• OPKO Health, Inc. (GenPath)
• Veracyte, Inc.

The post U.S. Prostate Cancer Testing Market – A Country Analysis: Focus on Type of Biomarker, Application, End User, and Region – Analysis and Forecast, 2022-2030 first appeared on CRI Report.

The global sustainable films for packaging market was estimated at $140.0 billion in 2021 and is expected to reach $276.2 billion by 2031, growing at a CAGR of 7.0% during the forecast period 2022-2031. The growth in the global sustainable films for packaging market is expected to be driven by an increasing focus on the circular economy and the growing awareness of its environmental benefits among end users and consumers. However, the lack of recycling technology and the high cost of raw materials are some key restraining factors for the market.

Market Lifecycle Stage

The global sustainable films for packaging market is in a growing phase. New trends, such as the development of bioplastics, are further expected to provide opportunities for the market to grow in the coming years.

Industrial Impact

With an increased worldwide focus on the circular economy, the shift toward eco-friendly industrial practices is increasing, thereby creating demand for sustainable products. The shift is more prominent in the food and beverages industry in regions such as Europe and North America.

Impact of COVID-19

The COVID-19 pandemic had a huge impact on the global sustainable films for packaging market. It altered the market in both positive as well as negative ways. During the COVID–19 pandemic, sectors that help meet necessities, such as providing food and supplies to consumers securely, were increasingly disrupted.

Market Segmentation

Segmentation 1: by Application

• Food and Beverage
• Pharmaceutical
• Consumer Goods
• Personal Care
• Consumer Electronics

Among different sustainable films used for packaging in end-use applications, the food and beverage segment is expected to be the largest application during the forecast period 2022-2031.

Segmentation 2: by Material Type

• Polypropylene (PP)
• Polyethylene (PE)
• Polyethylene Terephthalate (PET)
• Others (PLA and Cellulose)

Among different types of materials, the polyethylene segment led the market in 2021 and is estimated to lead the market during the forecast period 2022-2031 as well.

Segmentation 3: by Region

• North America – U.S., Canada, and Mexico
• South America – Brazil, Argentina, Chile, and Rest-of-South America
• Europe – Germany, France, Spain, Italy, and Rest-of-Europe
• U.K.
• Asia-Pacific and Japan – Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific and Japan
• China
• Middle East and Africa – U.A.E., Saudi Arabia, South Africa, Egypt, and Rest-of-Middle East and Africa

Europe led the sustainable films for packaging market in 2021 and is anticipated to uphold its dominance throughout the forecast period.

Recent Developments in Sustainable Films for Packaging Market

• In February 2022, Sealed Air increased its recyclable barrier display film portfolio to improve recyclability across European food supply chains. The company launched two new low-density polyethylene (LDPE) mechanical recycling and chemical recycling compatible Cryovac Brand Eco BDF films, namely, Eco BDF20M and Eco rBDF20M.
• In April 2022, ProAmpac announced the launch of its latest ProActive Recyclable R-2000S, which is made up of recyclable polyethylene material.
• In June 2021, Amcor plc launched AmPrima PE Plus ultra-clear and heat resistance films. The AmPrima PE Plus product uses raw materials which are ready for recycling processes and manufacturing. These films are easy-to-recycle and are effective at reducing carbon footprints.
• In November 2021, Rani Plast made significant additional investments to boost production capacity for recycled packaging film. Furthermore, the new lines would cut production waste, increase packaging film quality, and allow the company to employ other raw materials, such as recycled plastic granules.

Demand – Drivers and Limitations

Following are the demand drivers for the global sustainable films for packaging market:

• Growing Government and Industrial Initiatives to Reduce Plastic Waste
• Increasing Demand for Mono-Material Plastic Packaging

The market is expected to face some limitations too due to the following challenges:

• Lack of Technological Advancement around Recycling
• High Cost and Inadequate Production of Bio-Based Raw Materials

How can this report add value to an organization?

Product/Innovation Strategy: The product segment helps the reader understand the different types of materials available for sustainable films for packaging and their potential globally. Moreover, the study provides the reader with a detailed understanding of the different sustainable films for packaging applications in industries such as food and beverages, pharmaceutical, personal care, consumer goods, and consumer electronics.

Growth/Marketing Strategy: Business expansion, partnership, collaboration, and joint venture are some key strategies adopted by key players operating in the space. For instance, in February 2022, Sealed Air increased its recyclable barrier display film portfolio to improve recyclability across European food supply chains. The company launched two new low-density polyethylene (LDPE) mechanical recycling and chemical recycling compatible Cryovac Brand Eco BDF films, namely, Eco BDF20M and Eco rBDF20M.

Competitive Strategy: Key players in the global sustainable films for packaging market analyzed and profiled in the study involve sustainable packaging film providers. Moreover, a detailed competitive benchmarking of the players operating in the global sustainable films for packaging market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names in this market are:

• Amcor plc
• Rani Group
• Innovia Films
• Mondi
• Berry Global Inc.
• UFlex Limited
• TORAY ADVANCED FILM CO., LTD.
• Pregis LLC
• Constantia Flexibles
• Sealed Air
• Transcontinental Inc.
• ProAmpac
• DUNMORE
• Bleher Folientechnik GmbH
• ePac Holdings, LLC.
• Cosmo Films

The post Sustainable Films for Packaging Market – A Global and Regional Analysis: Focus on Material, Applications, and Region – Analysis and Forecast, 2022-2031 first appeared on CRI Report.

Market Segmentation

• Product (Instruments, Consumables, and Software)
• Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray, In-Situ Hybridization (ISH), and Other Technologies)
• Application (Drug Discovery and Development, Diagnostics, Cell Biology, Single Cell Analysis, Gene Expression, and Other Applications)
• End User (Academic and Research Institutions, Biotechnology and Pharmaceutical Companies, and Other End Users (Hospitals, Clinics, and Diagnostics Labs)

Regional Segmentation

• North America: U.S., Canada
• Europe: Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific: China, India, Japan, Australia, Singapore, and Rest-of-Asia-Pacific
• Latin America: Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World (RoW)

Market Growth Drivers

• Increasing Application of NGS and RNA-Sequencing in Transcriptomics Research
• Increase in Adoption of Personalized Medicine
• Continuous Advancement in the Products for Transcriptomics Research

Market Challenges

• High Cost and Maintenance of Next-Generation Sequencing and RNA-Sequencing Platform
• Lack of Tools for Computational Analysis
• Lack of Infrastructure and Expertise

Market Opportunities

• Expansion into New Research Application
• Expansion of Biomarker Discovery
• Use of Toxicogenomic to Promote Transcriptomics Research

Key Companies Profiled

10x Genomics, Agilent Technologies, Inc., ANGLE plc, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Bio-Techne, BioSypder, Inc., Cytiva, Fluidigm Corporation, Illumina, Inc., Menarini Silicon Biosystems, NanoString, Pacific Biosciences of California, Inc., PerkinElmer Inc., QIAGEN, Takara Bio Inc., Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

• How is next-generation sequencing technology affecting the transcriptomics market?
• What are the major market drivers, challenges, and opportunities in the global transcriptomics market?
• What are the underlying structures resulting in the emerging trends within the global transcriptomics market?
• How is the COVID-19 pandemic impacting the global transcriptomics market landscape?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to transcriptomics?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region for the development of transcriptomics?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
• What are the growth opportunities for the companies in the region of their operation?
• What are the major applications for the companies in the region of their operation?
• Who are the leading players with significant offerings in the global transcriptomics market?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the current unmet needs that are being faced in the global transcriptomics market?

Market Overview

The growth of the transcriptomics market is expected to be driven by the decrease in the cost of sequencing, the global increase in the application of next-generation sequencing and RNA sequencing in transcriptomics, and the advancement of the products. However, there are significant challenges restraining the market growth, such as the high cost and maintenance of next-generation sequencing and RNA sequencing platforms and the lack of tools for computational analysis. The transcriptomics approach has been able to decipher the mechanism of complex bulk tissue, giving a deep understanding of heterogeneous cell populations. With the co-analysis of molecules, such as RNA, and protein, at a single cell level, the researchers are able to unearth the regulation mechanism associated with RNA transcription and protein translation.

The healthcare experts have found the transcriptomics market to be one of the stable markets, and the global market is predicted to grow at a CAGR of 20.11% during the forecast period 2021-2031.

The transcriptomics market is an emerging market with huge growth potential. Recent technological advancements are facilitating the adoption of the technology at a rapid pace. Transcriptomics offers the ability to isolate a single cell with specific phenotypes from a heterogeneous mixture, along with gene expression analysis and protein expression analysis. The unique feature of transcriptomics technology to integrate the data from various molecules and from different cells to study cell-to-cell differentiation enables the study of mechanisms that are visible at a transcriptomic level.

Competitive Landscape

The growth in this market is expected to be driven by the decrease in the cost of sequencing, the global increase in the application of next-generation sequencing and RNA sequencing in transcriptomics, and the advancement of products launches. The growth of other technologies, such as in-situ hybridization, can be attributed to the increased clinical research to understand the involvement of molecular pathology in the diagnosis and prognosis of genetic disorders. Based on region, North America holds the largest share in the market, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

The post Transcriptomics Market – A Global and Regional Analysis: Focus on Product, Application, Technology, and End User – Analysis and Forecast, 2021-2031 first appeared on CRI Report.